Table 3 Percentage change in CTX and P1NP levels from baseline (AECOPD) to 1- and 3-month follow-up excluding patients who had osteoporosis and those who had taken bisphosphonates, denosumab or synthetic human parathyroid within the 12 months before inclusion

CTX

Low-dose group

257

− 26% (− 36, − 14%);

p = 0.0002

−14% (− 27, 1%);

p = 0.063

CTX

High-dose group

257

−32% (− 40, − 22%);

p < 0.0001

− 30% (− 40, − 19%);

p < 0.0001

Relative difference between treatment groups^a

8% (−10, 31%);

p = 0.40

23% (0, 51%);

p = 0.049

P1NP

Low-dose group

22

65% (49, 83%);

p < 0.0001

55% (38, 73%);

p < 0.0001

P1NP

High-dose group

22

62% (48, 78%);

p < 0.0001

60% (44, 78%);

p < 0.0001

Relative difference between treatment groups^a

2% (−11, 16%);

p = 0.80

−4% (− 17, 12%);

p = 0.63

 P1NP/CTX ratio

 Low dose group

0.10

2.29 (1.98–2.65)

p < 0.0001

2.20 (1.89; 2.56)

p < 0.0001

 P1NP/CTX ratio

 High dose group

0.10

2.22 (1.89–2.60)

p < 0.0001

1.80 (1.53; 2.12)

p < 0.0001

Relative difference between treatment groups^a

0.97 (0.81; 1.17)

p = 0.74

0.82 (0.67; 1.00)

p = 0.052